Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Depreciation & Amortization (CF) (2020 - 2023)

Historic Depreciation & Amortization (CF) for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $289000.0.

  • Candel Therapeutics' Depreciation & Amortization (CF) rose 6235.96% to $289000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $955000.0, marking a year-over-year increase of 3082.19%. This contributed to the annual value of $1.0 million for FY2024, which is 0.0% changed from last year.
  • Per Candel Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $289000.0 for Q4 2023, which was up 6235.96% from $200000.0 recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' Depreciation & Amortization (CF) ranged from a high of $289000.0 in Q4 2023 and a low of $6000.0 during Q4 2020
  • Its 4-year average for Depreciation & Amortization (CF) is $140571.4, with a median of $178000.0 in 2021.
  • The largest annual percentage gain for Candel Therapeutics' Depreciation & Amortization (CF) in the last 5 years was 286666.67% (2021), contrasted with its biggest fall of 5333.33% (2021).
  • Quarter analysis of 4 years shows Candel Therapeutics' Depreciation & Amortization (CF) stood at $6000.0 in 2020, then soared by 2866.67% to $178000.0 in 2021, then changed by 0.0% to $178000.0 in 2022, then soared by 62.36% to $289000.0 in 2023.
  • Its last three reported values are $289000.0 in Q4 2023, $200000.0 for Q3 2023, and $236000.0 during Q2 2023.